Kahalalide F

Drug Profile

Kahalalide F

Alternative Names: KF; PM 92102

Latest Information Update: 04 Apr 2011

Price : $50

At a glance

  • Originator PharmaMar
  • Class Depsipeptides
  • Mechanism of Action ERBB-3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Liver cancer; Malignant melanoma; Non-small cell lung cancer; Psoriasis

Most Recent Events

  • 17 Jun 2009 No development reported - Phase-II for Liver cancer in Spain (IV)
  • 17 Jun 2009 No development reported - Phase-II for Malignant melanoma in Europe (IV)
  • 17 Jun 2009 No development reported - Phase-II for Non-small cell lung cancer in Europe (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top